Form 4: Syndax R&D Head Boosts Equity Holdings

Syndax Pharmaceuticals' Head of R&D and CMO, Nicholas A.J. Botwood, received substantial equity awards including restricted stock units and stock options.

Summary

• Nicholas A.J. Botwood, Head of R&D and CMO of Syndax Pharmaceuticals Inc (SNDX), was awarded 24,000 restricted stock units (RSUs) on February 4, 2026.
• An additional 36,000 performance-based restricted stock units (RSUs) were awarded to Mr. Botwood on the same date.
• Mr. Botwood also received 144,700 stock options with an exercise price of $20.43 per share, expiring on February 4, 2036.
• The 24,000 RSUs will vest annually in one-third increments over three years, contingent on continued service.
• The 36,000 performance-based RSUs are contingent upon achieving pre-established performance metrics approved by the Company's Compensation Committee, also subject to continued service.
• The 144,700 stock options will vest monthly over a four-year period, with 1/48th vesting each month.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development. The significant equity awards to a key R&D executive align management's interests with shareholders and incentivize long-term performance, which is generally favorable.

Positives

• The significant equity awards align the interests of a key executive (Head of R&D, CMO) with those of shareholders, promoting long-term value creation.
• Performance-based RSUs incentivize the achievement of specific company goals, potentially driving strategic success and shareholder returns.
• The awards demonstrate the company's commitment to retaining and motivating senior leadership.

Future Outlook

The equity awards, particularly the performance-based RSUs and long-term stock options, suggest a strategic focus on future growth and the achievement of specific operational milestones over the next three to four years, contingent on the continued service of a key R&D executive.

Industry Context

StockSavvy.ai notes that significant equity awards, especially those tied to performance metrics and long-term vesting schedules, are a common practice in the biotechnology and pharmaceutical industries. This approach is designed to retain critical talent, particularly in R&D roles, and align executive incentives with the lengthy development cycles and high-risk, high-reward nature of drug discovery and commercialization. This filing reflects a standard compensation strategy aimed at fostering long-term commitment and success.

Comparison to Industry Standards

• The structure of these awards, combining time-based RSUs, performance-based RSUs, and stock options, is consistent with executive compensation packages observed at comparable biotech firms such as Regeneron Pharmaceuticals (REGN) or Vertex Pharmaceuticals (VRTX), which frequently utilize a mix of equity vehicles to incentivize long-term value creation.
• The vesting schedules (3-year for time-based RSUs, 4-year for options) are standard for executive retention and performance alignment in the sector, mirroring practices seen in companies like Amgen (AMGN) or Gilead Sciences (GILD) for their senior scientific and medical officers.
• The inclusion of performance metrics for a portion of the RSUs is a growing trend across the industry, reflecting a move towards more rigorous governance and direct linkage of pay to company achievements, similar to programs at Bristol Myers Squibb (BMY) or Pfizer (PFE).

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of executive incentives with long-term company performance and value creation.
• Employees: May signal confidence in the company's future and its ability to attract and retain key talent, potentially boosting morale.

Next Steps

• The 24,000 time-based RSUs will vest annually in one-third increments on the anniversary of the vesting commencement date over the next three years.
• The 36,000 performance-based RSUs will vest upon the achievement of pre-established performance metrics, as approved by the Compensation Committee.
• The 144,700 stock options will vest monthly over the next four years, with 1/48th vesting each month.

Key Dates

Keywords

Syndax Pharmaceuticals, SNDX, SEC Form 4, Insider Transaction, Restricted Stock Units, RSUs, Stock Options, Executive Compensation, Equity Awards, Corporate Governance, Biotechnology